<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104309">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047461</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1101-MCD-201</org_study_id>
    <secondary_id>2013-002701-56</secondary_id>
    <nct_id>NCT02047461</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP</brief_title>
  <official_title>A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ALXN1101 in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharma International Sarl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharma International Sarl</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will include a screening period, a 6-month treatment period, and a 30-month,
      long-term extension period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive daily IV infusions of ALXN1101 starting on Day 1. After a prescribed
      period, dosing will increase monthly based on defined patient safety measures.  After month
      6, patients will continue daily dosing through month 36 at their last tolerated dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of ALXN1101</measure>
    <time_frame>First 6 months of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The type, number and frequency of adverse events and severity of adverse events (AEs) and serious adverse events (SAEs)
Change from baseline in: clinical laboratory assessments, findings on  physical examination, vital sign measurements, and EEG results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of ALXN1101</measure>
    <time_frame>First 6 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentration (Cmax), time to maximum observed plasma concentration (tmax), area under the plasma concentration-time curve (AUC), and terminal half-life (t½)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALXN1101 on urine and blood biomarkers</measure>
    <time_frame>Up to Month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in urine and blood biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALXN1101 on neurologic function including motor examination</measure>
    <time_frame>Up to Month 36</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline on repeated Neurologic examinations such as tone, strengthen and reflexes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term safety of ALXN1101</measure>
    <time_frame>Up to Month 36</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The type, number and frequency of adverse events and serious adverse events (SAEs)
Change from baseline in: clinical laboratory assessments, findings on physical examination, vital sign measurements, and EEG results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ALXN1101 on cognitive functions</measure>
    <time_frame>Up to Month 36</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline in cognitive function using age appropriate measures of cognition, eg. Wechsler Preschoool and Primary Scale of intelligence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>MoCD Type A</condition>
  <condition>Molybdenum Cofactor Deficiency</condition>
  <arm_group>
    <arm_group_label>ALXN1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily IV infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1101</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>ALXN1101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Male or female patients with a genetically confirmed diagnosis of MoCD Type A (MOCS1
        mutation) and who are currently treated with rcPMP infusions.

        Exclusion Criteria:

        - Current or planned treatment with another investigational drug or device, with the
        exception rcPMP treatment through Day -1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharma International Sàrl (Sponsor)</last_name>
    <email>clinicaltrials@alxn.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion International Sàrl (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexion International Sàrl (sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>GZ Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexion Pharma International Sarl (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexion International Sàrl (Sponsor)</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molybdenum cofactor deficiency (MoCD)</keyword>
  <keyword>molybdenum cofactor (MoCo) biosynthesis</keyword>
  <keyword>sulfite oxidase (SO)</keyword>
  <keyword>xanthine dehydrogenase</keyword>
  <keyword>aldehyde oxidase</keyword>
  <keyword>S sulfocysteine (SSC)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Molybdenum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
